Introduction
In the United States alone, the population of oldest-old (over 80 years of age) is expected to increase from 11.7 million in 2012 to more than 20 million in 2030 [1] . As the risk to fracture increases exponentially with age [2] , the number of fractures is expected to increase dramatically as a consequence. At the age of 50, the risk of sustaining a fragility fracture (low energy trauma fracture) during the remaining lifetime is 50% for women and 20% for men [2] . Already today, patients with fragility fractures require more in-hospital days than breast and prostate cancer combined, a figure exceeded only by those with stroke [3] . The increase in fracture rates will result in enormous health care cost; already the yearly fracture-related cost of osteoporosis in the United States is estimated to $17 billion [4] . Hip fracture is the most severe fracture and associated with increased morbidity and mortality [5] . Between 40% and 60% of hip fracture, survivors are not likely to recover their This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
prefracture level of mobility [6] , and the oneyear mortality is increased by 8-36% [7, 8] .
There is strong evidence for secondary fracture prevention with the bisphosphonate alendronate, a treatment that results in a 40% relative risk reduction (RRR) of hip fractures in postmenopausal women [9] . However, as older patients often suffer from multiple comorbidities preventing the participation in clinical trials, none of the large randomized trials (RCTs) included a significant proportion of patients above the age of 80 years [10] . An RCT investigating the effect of risedronate on old women (n = 3886, aged 80-89) found no clear hip fracture risk reduction [11] . However, that study included women with one nonskeletal risk factor for hip fracture or low BMD, whereas a previous fracture was not required. Thus, there is insufficient evidence regarding the effectiveness and safety of oral bisphosphonate treatment amongst the oldest-old.
The purpose of this study was to investigate whether alendronate (which accounts for 93% of all oral bisphosphonate use in Sweden [12] ) prescribed to older patients (≥80 years) with prior fracture was related to a reduced risk of hip fracture and sustained safety in a large cohort of older men and women.
Materials and methods

Study design
The risk of hip fracture and expected adverse events in older alendronate users and nonusers was investigated in a prospective observational register-based study, using four to one propensity score matching and multivariable Cox models.
Study population
The 'Fractures and fall injuries in the elderly cohort' (FRAILCO, [13] ) is a national cohort based on information from several Swedish national registers, linked in order to study associations regarding fractures, fall injuries, morbidity, mortality and medications. Patients were initially selected from the Senior Alert register, consisting of men and women ≥65 years, who underwent a fall risk assessment in connection to a visit to a healthcare facility in Sweden between 2008 and 2014 [14] . All patients were included in the register, without exclusion criteria. Senior Alert was originally designed to follow and support improvements in preventive care for older adults and encompasses more than 90% of all municipalities and counties throughout Sweden [14] . In 2014, it included approximately 22% of the Swedish population over 65 years of age [15] .
After excluding patients with probable registry errors as well as immigrants with insufficient background data, patients aged 80 years or older were selected. In order to emulate a secondary prevention setting, only patients with a prior fracture (index fracture) were included in the present study. Patients with severe kidney failure (N184-N185), that is not eligible for alendronate treatment, were excluded ( Fig. 1 ).
Ascertainment of alendronate treatment
Medication data were collected from the Drug Dispensation Register (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . Only patients being treatment na€ ıve at the time of the index fracture were included in the analysis either as case or control. Patients starting alendronate treatment after fracture were included as cases and compared to patients who never received any osteoporosis treatment after index fracture (controls). All patients with other known osteoporotic treatments (risedronate, zoledronic acid, denosumab, testosterone, systemic oestrogens, strontium ranelate, PTH-analogues and selective oestrogen receptor modulators) before the risk assessment were excluded from the analyses. Alendronate patients with <3 months of treatment or not currently treated (last dispensation expected to be consumed but not renewed) were also excluded. Currently treated was here defined as having access to alendronate for at least three months immediately before the risk assessment. In order to balance the groups, controls with <3 months between index fracture and risk assessment were excluded. Thus, the resulting alendronate variable represents use in the interval between index fracture and risk assessment and ongoing (current) at the time of the risk assessment (Figs 1 and 2) . Apart from the dichotomous alendronate variable, others were defined: alendronate treatment time was measured from the date of the first prescription after the index fracture to the date when the last prescription was used, truncated at the fall risk assessment date (time zero). Medication possession ratio (MPR) was calculated as the sum of the defined daily doses during the treatment time, divided by the treatment time resulting in a value between 0 and 1. Concomitant medication was accounted for if a retrieved prescription was expected to be used within 90 days before baseline and if there were at least two retrieved prescriptions registered. 
Definition of fracture
Fracture information was collected from the National Patient Register. All nonmalignant fracture diagnoses in ICD-10 regardless of type of trauma were included, apart from head fractures (Table S1 ). If a fracture diagnosis on the same skeletal site (ICD-10 two digits) was repeated within five months, it was discarded as it most likely was a revisit and not a new fracture.
Ascertainment of hip fracture
The main outcome, hip fracture, was defined as a fractured femoral head, neck, trochanter or subtrochanteric part of femur, in combination with a code for surgical procedure (Table S2 ). Identification of hip fracture using this procedure has high accuracy [16] . Time to hip fracture was calculated from the time of the risk assessment to the actual hip fracture, and censored for death (from the Cause of Death Register), emigration (from Statistics Sweden) and end of study period (31 December 2014).
Ascertainment of other outcomes
Other outcomes included major osteoporotic fractures, any fracture (Tables S1 and S2) , as well as death. Dyspepsia, acid reflux and esophagitis were combined from the National Patient Register to analyse mild upper gastrointestinal (UGI) symptoms as a possible adverse outcome during followup after risk assessment. Also, peptic ulcer, druginduced osteonecrosis and femoral shaft fractures were analysed (Table S3 ). Time to mild UGI symptoms and peptic ulcer, respectively, were also censored for death, emigration and end of study period. Information regarding cause of death was retrieved from the National Causes of Death Register.
Assessment of morbidity and covariates
All data regarding prior illnesses before risk assessment were collected from Tables S2,  S4 -S9. Characterization of mobility status, general condition, food and liquid intake at the time of risk assessment was performed using questions from the validated RAPS or Norton scales [18] . Weight and height were measured at the time of the risk assessment and collected from Senior Alert.
Statistical analyses
Nontreated patients were matched through a four to one propensity score matching according to age, sex, weight, height, rheumatoid arthritis, alcoholrelated diseases, previous glucocorticoid treatment, the individual diseases included in both secondary osteoporosis definition (Table 1) and Charlson comorbidity index as well as time since index fracture, previous vertebral fracture, previous hip fracture, number of previous fractures, previous fall injury and osteoporosis diagnosis (M80-M81) [19, 20] . Differences between the matched controls and the treated patients were investigated using To address the issue of potential persistence bias and the possible healthy adherer effect [21] , we analysed the persistence of the commonly used drug acetylsalicylic acid and compared current alendronate users with their matched untreated controls. A P-value <0.05 was considered significant. The Cox assumption of proportional hazards was tested for all outcomes using a time-dependent Cox model with a linear interaction term between time and alendronate.
Results
The present study included a total of 9805 patients of which 1961 had current alendronate treatment at the time of the risk assessment and 7844 matched controls that never had had any osteoporosis medication (Table 1 ). The accumulated follow-up time or time at risk was 14 800 years, of which 3135 years in the treated group and 11 666 years in the untreated group. The mean time at risk was significantly longer in the treated group compared to the untreated ( Table 2 ). All patients in the treated group were currently being treated and had a mean previous treatment time of 3.5 years, during which the mean medication possession ration was 91%. The primary inclusion sites were hospital wards (46%) or nursing homes (38%), with the remaining of the patients included at residential home care (8.6%), health centres (4.5%) and rehabilitation units (3.1%). In the total cohort, 89% of the patients were characterized to be in good or Apart from osteoporosis being more common amongst the treated patients, there were no significant differences in prevalent diseases or risk factors for fracture, between the treated and untreated patients (Table 1 ). There were no significant differences between groups in terms of general condition or food portion sizes, whilst reduced liquid intake was significantly more common in the untreated group (Table S10) . At baseline, alendronate-treated patients more frequently used diuretics, statins, calcium channel blockers, angiotensin-converting enzyme inhibitors and opioids but less frequently used benzodiazepines than patients not treated with alendronate (Table S11) . Calcium and vitamin D supplementation, normally prescribed together with alendronate, was used by 85% in the alendronate group and by 30% in the untreated group.
Hip fracture incidence in the alendronate-treated patients was significantly lower than in the untreated patients, in both percentage and per 100 000 person-years (Table 2a) . In a crude Cox model, alendronate treatment was associated with a 38% reduced risk of hip fracture. The association was somewhat attenuated, but remained highly significant in a multivariable Cox models (Tables 2a and 3 ; Fig. 3 ). The three-year absolute risk reduction (ARR), based on the multivariable Cox models, was estimated to 3.9%, corresponding to number needed to treat (NNT) of 26. These associations were maintained for both men and women analysed separately (Table S11 ). The interaction term of age and alendronate was not associated with hip fracture risk in a multivariable Cox model (P = 0.49), indicating no age-dependent alendronate association. In the whole cohort, 6935 patients had suffered a previous fall injury.
In the multivariable Cox model, alendronate was associated with hip fracture in these patients (hazard ratio (HR) 0.64 (0.47-0.87)), but the association was not significant in patients without a prevalent fall injury (n = 2870, HR 0.72 (0.45-1.18). There was no significant interaction between alendronate use (yes/no) and previous fall injury (P = 0.85 for the interaction term).
Repeating the multivariable-adjusted Cox model with alendronate treatment length as a predictor instead of alendronate yes/no revealed that treatment length was associated with a 9% reduced risk of hip fracture per year of treatment. Using the same Cox model with medication possession ratio (MPR) instead of alendronate treatment length, we found that alendronate MPR was associated with a 4% reduced risk of hip fracture per 10 per cent improvement of MPR (Table 2a) .
Alendronate treatment was also associated with significant risk reductions in major osteoporotic and any fracture, in both crude and multivariable Cox models (Table 2a ).
The multivariable-adjusted cox models used to study the associations between alendronate and hip fracture were essentially unaffected when also including adjustments for (i) general condition, portion size and liquid intake (HR for alendronate treatment 0.66 (0.51-0.86); (ii) inclusion site (HR 0.67 (0.52-0.87)); and (iii) mobility status HR 0.65 (0.49-0.85).
The mortality rate in the alendronate-treated group was significantly lower both in percentage and per 100 000 person-years (Table 2b) . Using a multivariable Cox model, alendronate treatment was associated with a 12% reduced mortality risk (Table 2b ). Analysis on causes of deaths revealed a nonsignificant trend that hip fracture-related deaths were reduced with alendronate, whilst there were no significant differences in deaths related to cancer, stroke or acute myocardial infarction between treated and untreated patients (Table S12 ).
The incidence of mild UGI symptoms (dyspepsia, reflux or esophagitis) was significantly higher amongst the alendronate-treated compared to the untreated group (Table 2b) . In a multivariable Cox model, alendronate treatment was associated with 58% increased risk of mild UGI symptoms. Using the interaction term in the adjusted Cox model revealed no significant age-dependent alendronate association with risk of UGI (P = 0.81). The threeyear absolute risk increase was 1.1% corresponding to a number needed to harm (NNH) of 91.
Treatment was not associated with an increased risk of incident peptic ulcers in a multivariable Cox model (Table 2b) .
Drug-induced osteonecrosis was rare with only one case in the treated group. Atypical femur fractures (AFFs) cannot be specifically identified using register data, but the frequency of femoral shaft fractures (including AFFs) was investigated. The incidence of femoral shaft fractures was low and not significantly higher amongst treated patients (Table 2b) .
Medication persistence to acetylsalicylic acid did not differ between current alendronate users and nonalendronate users ( Figure S1 , P = 0.91).
The Cox assumption of proportional hazards was fulfilled for all outcomes (Table S14) .
Discussion
In the present study of patients aged 80 years and older, we found robust and consistent associations between alendronate use, regardless of treatment definition, and reduced risk of hip fractures.
These results are consistent with a previous randomized trial, reporting a maintained RRR of a composite end-point of hip, spine and wrist fracture, with increasing age, although patients were less than 80 years at inclusion [22] . There are no available studies with adequate sample size and power investigating the effect of alendronate on hip fracture risk in patients older than 80 years [10] . Risedronate has shown a remarkable 83% risk reduction in vertebral fracture in an old population (n = 1392, aged 80-98, mean (SD) 83.0 (3.0)), but the risk of nonvertebral fractures was not significantly lower; however, unlike in our study, not all participants had a prior fracture [23] .
Screening women aged 65 years and older followed by treatment with alendronate resulted in cost savings and QALY increases if the yearly alendronate cost is USD 200 or less [24] . The current cost of alendronate is less than a third and our study population is older indicating a highly favourable cost-benefit perspective for alendronate treatment amongst the oldest-old.
Treating older and often frail patients could increase the rate of known adverse events such as UGI symptoms and possibly be harmful. We observed indeed an increased risk of mild UGI symptoms, but the NNH for current users was 91, as compared to the NNT of 26 for hip fracture, which in all could be considered as a favourable risk-benefit ratio. As no significant increased risk of peptic ulcers, femoral shaft fracture or mortality was found, and the cases of drug-induced osteonecrosis were too few to analyse, our data indicate that alendronate treatment is safe, also in very old patients. Despite the relatively large sample size, the short follow-up time may have limited the ability to detect rare adverse events such as atypical femur fractures, linked to long treatment durations. However, a recent nested case control study showed an acceptable balance of risk and benefit even with long alendronate treatment [25] . We found that treatment was associated with a 12% reduction in mortality, which is in line with a metaanalysis of RCTs demonstrating a 10% risk reduction in mortality with antiresorptive treatment [26] . Deaths in relation to hip fracture were less common, although not significantly, in alendronate users (Table S13) .
To minimize the uncertainty of selection bias, we used propensity score matching and obtained wellbalanced groups of treated and untreated patients. Furthermore, we adjusted for Charlson morbidity index, and other potential confounders in multivariable Cox models, which did not substantially affect the observed associations. The lack of significant differences in acetylsalicylic acid medication persistence between alendronate-treated versus untreated patients indicates there was no healthy adherer effect. Furthermore, investigating concomitant medication in alendronate-treated and untreated patients did not indicate that alendronate users were healthier than nonusers. Despite these performed measures to control for possible bias, we cannot rule out that other selection factors for choosing which patients to treat could exist, and as a result, the observed associations could have been affected by other differences in patient characteristics not controlled for in this study.
The relatively high fallout from censored cases is a consequence of the cohort being old (all patients were 80 years or older -in order to study alendronate in the oldest-old) with high mortality and the relatively short follow-up time (mean 18 months), whilst some cases have up to 7 years It has been argued that pharmacological treatment to prevent hip fracture is ineffective and that other measures such as physical activity, cessation of smoking and optimizing the diet should be prioritized instead [27] . Although no adequately powered randomized trial has been able to show that any of these measures can prevent hip fractures, there is available evidence supporting interventions to prevent falls [28] . Nonpharmacological measures including fall prevention are therefore currently recommended in addition to pharmacological treatment in clinical guidelines for treating osteoporosis [29, 30] . In the present study, we observed an association between alendronate treatment and reduced risk of hip fracture in the subset of patients (n = 6935) who had experienced a previous fall injury. Although this association was similar in patients without a fall injury, the association did not reach statistical significance, which could be due to the relatively small number of patients in that group (n = 2870). Lack of a significant interaction between alendronate treatment and prevalent fall injury regarding the association with hip fracture indicates a similar role of alendronate irrespective of fall history.
A limitation of the present study is the lack of data regarding bone densitometry and fracture trauma type. However, there is evidence that trauma type does not discriminate osteoporotic from nonosteoporotic fractures [31] . It should be acknowledged that treatments with zoledronic acid have become more widely used during recent years in Sweden [32] , and are rarely registered in the Drug Dispensation Register as it is provided by hospital osteoporosis clinics. Therefore, it is likely that some of the patients in our control group could have received this treatment, which would then have reduced the fracture risk in the control group, resulting in attenuated associations between alendronate and hip fracture risk seen in our population. Furthermore, the proportion of patients with an osteoporosis diagnosis was larger in the alendronate treatment group than in the control group. Acknowledging these sources of bias, the observed relative risk reduction in our cohort of 34% for hip fractures (compared to the 40% reduction reported in RCTs) may be slightly underestimated [9] . Our results emanate from a primarily Caucasian population and may not be generalizable to other populations.
In conclusion, alendronate treatment was associated with reduced hip fracture risk in the oldest-old. These results suggest that alendronate treatment in the oldest-old is effective and safe, and should be considered in older patients in order to reduce the high fracture rates in this age group.
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